Faster diagnosis of sepsis pathogens

Microbial pathogens can be diagnosed unambiguously and within just 24 hours by means of high-throughput sequencing of their genetic makeup and special bioinformatics evaluation algorithms. Fraunhofer researchers have validated this in a clinical study with sepsis patients. The researchers present the NGS diagnosis platform at Medica in Düsseldorf from November 13–17, 2017.

It is estimated that in Germany alone around 150,000 people suffer from sepsis every year; despite medical advances, between 30 and 50 percent of the patients still die of the consequences. One of the reasons for the high mortality rate: the diagnosis often comes too late for the specific lifesaving therapy with antibiotics that only combat the causative pathogen. In general the sepsis pathogens are detected by means of so-called blood cultures in which the pathogenic organism from blood samples of the patients are cultivated in the laboratory. Here, two to five days pass before the pathogens have grown and a result is available. In addition, blood culture usually only delivers a positive result in 10 to 30 percent of cases thus helping the treating physician in his therapy decision in the minority of patients.

Due to rapid progress in nucleic acid analysis, the currently available high-throughput technologies (NGS, Next-Generation Sequencing) make it possible to sequence the complete genome of organisms within just a few hours and to align them against known gene sequences.

On the basis of these technologies researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB have developed an alternative diagnostic platform for sepsis. This enables them to identify bacteria, fungi or viruses directly by means of a sequence analysis of their DNA – without having to cultivate the pathogens beforehand in the laboratory. In clinical studies that the researchers carried out in cooperation with Heidelberg University Clinic, they have validated their diagnostic method with blood samples from sepsis patients. Here, they identified the infectious microorganisms by means of the high-throughput sequencing of DNA circulating freely in the blood (CNAPS, Circulating Nucleic Acids in Plasma and Serum).

Rapid one-step identification of bacteria, viruses and fungi

“With our next-generation sequencing diagnostic method we were able to determine within just 24 hours which pathogens the patients were infected with,” Dr. Kai Sohn, head of the “Functional Genomics” working group at Fraunhofer IGB, explains. “As a result of the direct sequencing of the DNA of a blood sample, the time-consuming step of cultivating the microorganisms in the lab is no longer necessary. In this way we can
also identify those pathogens that are more difficult to grow under laboratory conditions,” says Dr. Sohn.

A further advantage: If the samples contain not only the DNA of bacteria, but also that of viruses or fungi, these are sequenced, analyzed and identified as well. “For example, in our study we were able to identify a viral pathogen as the cause of a patient’s illness. Yet the patient’s blood culture showed a negative result because here only bacteria can be detected,” the scientist explains.

The method provides both qualitative and quantitative results at the same time. “With our technology, we can recognize on the basis of the number of genome fragments which pathogens are abundant in the patient and which are already responding to therapy,” Dr. Sohn points out. This permits the physician to immediately implement further targeted therapeutic measures instead of allowing valuable time to pass employing incorrect medication.

**Bioinformatics algorithms identify relevant pathogens**

Over 99 percent of the DNA freely circulating in the blood plasma is of human origin – thus identifying the sepsis pathogens resembles the proverbial search for a needle in a haystack. The researchers therefore use special software programs to compare the sequenced fragments with a genome database into which they have entered publicly available DNA sequences of bacteria, fungi and viruses.

However, not every microorganism that is identified is necessarily also the cause of the sepsis. One of the greatest challenges in the evaluation of the sequencing data is therefore to assess whether the finding differs from the statistically expected result. In order to be able to answer this decisive question, Philip Stevens, a bioinformatics specialist, developed a special algorithm in his doctoral thesis at the Center for Integrative Bioinformatics Vienna (CIBIV) and the Institute of Interfacial Process Engineering and Plasma Technology (IGVP) of the University of Stuttgart.

The centerpiece of the diagnostic method, for which a patent is pending, compares the sequencing results with sequenced fragments from the blood of healthy test persons. “In this way the algorithm provides us with a score with which we can assess the significance of the data and can exclude the microbial “background noise”, i.e. harmless bacteria of our skin or intestinal flora, as diagnostically relevant,” Stevens explains. The clinical study showed that the computed diagnoses correlated closely with those of the blood culture and, in addition, a multiplicity of pathogens could be found by the new diagnostic method.
Identifying antibiotic resistances

The resistance of bacteria to commonly used antibiotics such as methicillin, vancomycin or tetracycline is acquired via corresponding resistance genes. Therefore high-throughput sequencing makes it possible, in the same analysis, to identify both the biological species of the pathogen and its resistance genes. This also helps the physician treating the patient to set in motion a targeted therapy.

Further development

In order to further shorten the time from sample to final diagnosis, the scientists are examining how the method can be transferred to more recently developed sequencing platforms. With nanopore-based sequencing, for example, which is currently in the test phase, DNA can be sequenced in an even shorter time than previously. Thus in future the specific diagnosis of infections would be possible within a period of six to eight hours. The validity of the method is evaluated by clinical experts in another study, whose data will be published shortly. The positive results obtained by the method were considered as 96 percent plausible. A multicenter validation study with leading clinical partners is in preparation and will begin in early 2018.

Fraunhofer IGB presents sepsis diagnostics by means of next-generation sequencing at Medica in Düsseldorf from November 13–17, 2017 at the Fraunhofer joint stand (Hall 10, Stand G05).

The studies were published in following journals:


High-throughput sequencing of sepsis pathogens at Fraunhofer IGB.
(1) Automated DNA isolation allows up to 44 specimens to be processed at the same time.
(2) The sequencing flowcell is the carrier, to which DNA fragments are bound. Here the simultaneous high throughput parallel sequencing proceeds.

(© Fraunhofer IGB) | Picture in printing quality:
www.igb.fraunhofer.de/press

Reprints free of charge. A voucher copy is appreciated in case of publication.

Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB | Nobelstrasse 12 | 70569 Stuttgart | Germany |
www.igb.fraunhofer.de

Contact R&D Department
Dr. Kai Sohn | Phone +49 711 970-4055 | kai.sohn@igb.fraunhofer.de
Dr. Silke Grumaz | Phone +49 711 970-4084 | silke.grumaz@igb.fraunhofer.de

Contact Press
Dr. Claudia Vorbeck | Phone +49 711 970-4031 | claudia.vorbeck@igb.fraunhofer.de

The Fraunhofer-Gesellschaft is the leading organization for applied research in Europe. Its research activities are conducted by 67 institutes and research units at locations throughout Germany. The Fraunhofer-Gesellschaft employs a staff of 24,000, who work with an annual research budget totaling more than 2.1 billion euros. Of this sum, more than 1.8 billion euros is generated through contract research. More than 70 percent of the Fraunhofer-Gesellschaft’s contract research revenue is derived from contracts with industry and from publicly financed research projects. International collaborations with excellent research partners and innovative companies around the world ensure direct access to regions of the greatest importance to present and future scientific progress and economic development.

The Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB develops and optimizes processes and products in the fields of health, chemistry and process industry, as well as environment and energy. We combine the highest scientific standards with professional know-how in our competence areas – always with a view to economic efficiency and sustainability. Our strengths are offering complete solutions from the laboratory to the pilot scale. Customers also benefit from the cooperation between our five R&D departments in Stuttgart and the institute branches located in Leuna and Straubing. The constructive interplay of the various disciplines at our institute opens up new approaches in areas such as medical engineering, nanotechnology, industrial biotechnology, and environmental technology.